Cataract - Fidia Farmaceutici S.p.A.

CATARACT

CATARACT

Cataract is defined as any opacity of the crystalline lens, which is a result of a variety of changes, including alterations of lens cell structure, lens proteins or a combination of both.(1)

FIDIA’S COMMITMENT

Starting from its unparalleled experience in the field of hyaluronic acid, Fidia is committed to provide increasingly high-performance solutions to fill the needs of patients waiting for cataract surgery.

CAUSES

The opacity of the crystalline lens can develop because of many factors, age being a constant subliminal modifier. Former or current smoking, a long history of diabetes (more than 10 years), asthma or chronic bronchitis, and cardiovascular disease increased the risk of cataract, as well as drug intake and environmental exposition to UV light(2). About 8.3–25% of congenital cataracts are hereditary, generally caused by an intrauterine infection (e.g. rubella) or other prenatal insult(1).

SYMPTOMS

Cataracts most often present slowly and painlessly. Because of the insidious nature of progression many patients are often unaware of, and will not complain of, any dramatic changes in their vision.

The most common complaints consistent with a worsening cataract are blurred vision and/or glare, especially when driving at night, reduced visual acuity, contrast sensitivity, or color appreciation, increasing near-sightedness and monocular double vision or ghosting: seeing multiple images of one object(3).

MANAGING

Cataract surgery is one of the most commonly performed elective surgical procedures in westernized countries. It involves removing the eye’s clouded lens and replacing it with a clear synthetic version. Indication for surgery is when the vision falls below patients’ requirements.

Today it is performed under local anesthesia on an outpatient basis, and people are back to their normal lives within days. The success rate is high, and the rate of vision-threatening complications is relatively low.(3)

The great majority of patients experience an improvement in visual function, but 1 out of 10 patients perceive increased difficulties 6 months after surgery compared to the preoperative state(4).

PRODUCTS

FIDIAL PLUS® is a solutions of sodium hyaluronate indicated in ophthalmic surgical procedures such as cataract. It allows an effective protection of exposed tissues during surgery, such as the corneal endothelium. To be used only by specialists in hospitals or similar institutions.(5)

REFERENCES
1. Shiels A, Hejtmancik JF. Mutations and mechanisms in congenital and age-related cataracts. Exp Eye Res. 2017;156:95–102.
2. Elena Prokofyeva et al, Cataract prevalence and prevention in Europe: a literature review, Acta Ophthalmologica 2013.
3. Jay Thompson et al., CataractsPrimary Care: Clinics in Office PracticeVolume 42, Issue 3, September 2015, Pages 409-423.
4. Kessel, Line et al. “Indication for cataract surgery. Do we have evidence of who will benefit from surgery? A systematic review and meta-analysis.” Acta ophthalmologica vol. 94,1 (2016): 10-20.
5. Fidial Plus® Package insert.